Background: To testify whether multi-b-values diffusion-weighted imaging (DWI) can be used to ultra-early predict treatment response of concurrent chemoradiotherapy (CCRT) in cervical cancer patients and to assess the predictive ability of concerning parameters.
Methods: Fifty-three patients with biopsy proved cervical cancer were retrospectively recruited in this study. All patients underwent pelvic multi-b-values DWI before and at the 3rd day during treatment. The apparent diffusion coefficient (ADC), true diffusion coefficient (Dslow), perfusion-related pseudo-diffusion coefficient (Dfast), perfusion fraction (f), distributed diffusion coefficient(DDC) and intravoxel diffusion heterogeneity index(α) were generated by mono-exponential, bi-exponential and stretched exponential models. Treatment response was assessed based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1) at 1 month after the completion of whole CCRT. Parameters were compared using independent t test or Mann-Whitney U test as appropriate. Receiver operating characteristic (ROC) curves was used for statistical evaluations.
Results: ADC-T0 (p=0.02), Dslow-T0 (p<0.01), DDC-T0 (p=0.03), ADC-T1 (p<0.01), Dslow-T1 (p<0.01), ΔADC (p=0.04) and Δα (p<0.01) were significant lower in non-CR group patients. ROC analyses showed that ADC-T1 and Δα exhibited high prediction value, with area under the curves of 0.880 and 0.869, respectively.
Conclusions: Multi-b-values DWI can be used as a noninvasive technique to assess and predict treatment response in cervical cancer patients at the 3rd day of CCRT. ADC-T1 and Δα can be used to differentiate good responders from poor responders.
Figure 1

Figure 2

Figure 3
Loading...
Posted 15 Aug, 2020
On 06 Aug, 2020
On 05 Aug, 2020
On 04 Aug, 2020
On 04 Aug, 2020
Received 25 Jul, 2020
On 14 May, 2020
On 12 May, 2020
Received 12 May, 2020
Invitations sent on 11 May, 2020
On 30 Apr, 2020
On 29 Apr, 2020
On 30 Dec, 2019
On 21 Apr, 2020
Received 16 Apr, 2020
Received 16 Apr, 2020
On 14 Apr, 2020
On 12 Apr, 2020
Received 30 Mar, 2020
Received 29 Mar, 2020
On 19 Mar, 2020
On 12 Feb, 2020
Invitations sent on 14 Jan, 2020
On 30 Dec, 2019
On 26 Dec, 2019
On 25 Dec, 2019
On 24 Dec, 2019
Posted 15 Aug, 2020
On 06 Aug, 2020
On 05 Aug, 2020
On 04 Aug, 2020
On 04 Aug, 2020
Received 25 Jul, 2020
On 14 May, 2020
On 12 May, 2020
Received 12 May, 2020
Invitations sent on 11 May, 2020
On 30 Apr, 2020
On 29 Apr, 2020
On 30 Dec, 2019
On 21 Apr, 2020
Received 16 Apr, 2020
Received 16 Apr, 2020
On 14 Apr, 2020
On 12 Apr, 2020
Received 30 Mar, 2020
Received 29 Mar, 2020
On 19 Mar, 2020
On 12 Feb, 2020
Invitations sent on 14 Jan, 2020
On 30 Dec, 2019
On 26 Dec, 2019
On 25 Dec, 2019
On 24 Dec, 2019
Background: To testify whether multi-b-values diffusion-weighted imaging (DWI) can be used to ultra-early predict treatment response of concurrent chemoradiotherapy (CCRT) in cervical cancer patients and to assess the predictive ability of concerning parameters.
Methods: Fifty-three patients with biopsy proved cervical cancer were retrospectively recruited in this study. All patients underwent pelvic multi-b-values DWI before and at the 3rd day during treatment. The apparent diffusion coefficient (ADC), true diffusion coefficient (Dslow), perfusion-related pseudo-diffusion coefficient (Dfast), perfusion fraction (f), distributed diffusion coefficient(DDC) and intravoxel diffusion heterogeneity index(α) were generated by mono-exponential, bi-exponential and stretched exponential models. Treatment response was assessed based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1) at 1 month after the completion of whole CCRT. Parameters were compared using independent t test or Mann-Whitney U test as appropriate. Receiver operating characteristic (ROC) curves was used for statistical evaluations.
Results: ADC-T0 (p=0.02), Dslow-T0 (p<0.01), DDC-T0 (p=0.03), ADC-T1 (p<0.01), Dslow-T1 (p<0.01), ΔADC (p=0.04) and Δα (p<0.01) were significant lower in non-CR group patients. ROC analyses showed that ADC-T1 and Δα exhibited high prediction value, with area under the curves of 0.880 and 0.869, respectively.
Conclusions: Multi-b-values DWI can be used as a noninvasive technique to assess and predict treatment response in cervical cancer patients at the 3rd day of CCRT. ADC-T1 and Δα can be used to differentiate good responders from poor responders.
Figure 1

Figure 2

Figure 3
Loading...